NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
621 Västernorrland |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 38 | 0.8% | 4 | 0.1% | 2 | 0.0% | . | . | . | . | . | . | 4753 | 99.1% | 4797 | 100.0% |
ASCUS | 148 | 33.0% | 59 | 13.1% | 22 | 4.9% | 1 | 0.2% | . | . | 5 | 1.1% | 214 | 47.7% | 449 | 100.0% |
LSIL | 86 | 35.7% | 58 | 24.1% | 16 | 6.6% | 1 | 0.4% | . | . | . | . | 80 | 33.2% | 241 | 100.0% |
Atypical glandular cells/AGC | 12 | 46.2% | 3 | 11.5% | 5 | 19.2% | 5 | 19.2% | 1 | 3.8% | . | . | . | . | 26 | 100.0% |
Unclear atypia | 5 | 71.4% | 1 | 14.3% | 1 | 14.3% | . | . | . | . | . | . | . | . | 7 | 100.0% |
ASC-H | 13 | 20.3% | 9 | 14.1% | 39 | 60.9% | . | . | 1 | 1.6% | 2 | 3.1% | . | . | 64 | 100.0% |
HSIL | 3 | 4.8% | 4 | 6.5% | 51 | 82.3% | 4 | 6.5% | . | . | . | . | . | . | 62 | 100.0% |
Totalt | 305 | 5.4% | 138 | 2.4% | 136 | 2.4% | 11 | 0.2% | 2 | 0.0% | 7 | 0.1% | 5047 | 89.4% | 5646 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |